Context-dependent synthetic lethality - an emerging precision therapeutic approach

Area of Science:

• Oncology
• Genetics
• Pharmacology

Background:

• Precision oncology aims to expand beyond direct oncogene inhibition.
• Context-dependent synthetic lethality presents a promising strategy for this expansion.
• Understanding cancer-intrinsic vulnerabilities is key to identifying synthetic lethal opportunities.

Purpose of the Study:

• To describe genetic contexts and mechanistic themes underlying synthetic lethality in cancer.
• To highlight clinical successes and challenges in translating synthetic lethality into therapies.
• To provide a framework for discovering and developing novel synthetic lethal cancer therapies.

Main Methods:

• Identification of genetic contexts leading to cancer-intrinsic vulnerabilities.
• Analysis of common mechanistic themes (e.g., DNA repair defects, metabolic imbalances).
• Review of clinical case studies and functional genomics data for therapeutic index assessment.

Main Results:

• Synthetic lethality arises from diverse genetic contexts and mechanisms like DNA repair defects and metabolic imbalances.
• Clinical successes include poly(ADP-ribose) polymerase (PARP), hypoxia-inducible factor 2 (HIF-2), and Smoothened (SMO) inhibitors.
• Therapeutic index, informed by functional genomics, is critical for target prioritization and strategy.

Conclusions:

• Synthetic lethality offers a framework for developing more selective and durable cancer therapies.
• Understanding molecular mechanisms informs optimal therapeutic modality selection.
• Emerging approaches facilitate diverse synthetic lethal target discovery and drug development.